Many Dutch elite athletes and coaches face high levels of sport-related distress

Plus, news about Evom­mune, Maruho and Nous­com: In­nate Phar­ma gives up on Phase 1b tri­al for can­cer drug: The com­pa­ny was eval­u­at­ing la­cu­tam­ab as a

Tessera Ther­a­peu­tics, Flag­ship’s ma­jor bet on what it calls gene writ­ing, is let­ting go 13% to 14% of its work­force, a spokesper­son con­firmed to End­points